Related Experiment Videos
HER2/neu as a predictive factor in breast cancer
1Investigational Drug Branch for Breast Cancer, European Organization for Research and Treatment of Cancer, Brussels, Belgium.
Abstract:
One of the current trends in breast cancer research is to identify markers that can predict response to specific anticancer therapies; intense laboratory research and therapeutic trials are exploiting this strategy. The combination of cytotoxic drugs directed at the tumor population with the highest probability of being sensitive to them with molecules targeted at intracellular signaling and cell cycle control pathways, which may be deregulated as part of the malignant process, represents our best hope for improved survival in both early and advanced disease. The transmembrane tyrosine kinase receptor, HER2/neu, has been the subject of much investigation with respect to its prognostic value, predictive value, and as a target of antibody-mediated therapy. Retrospective evidence strongly suggests that HER2 overexpression is associated with decreased disease-free and overall survival in node-positive, and possibly also node-negative, breast cancer. Prospective trials have demonstrated that antibodies to HER2 can produce tumor responses in women with advanced disease that overexpresses this molecule. Moreover, the combination of such antibodies with cytotoxic drugs has been one of the few recent strategies to improve survival duration in metastatic breast cancer. The evidence supporting the role of HER2 as a factor predictive of response to hormone therapy and cytotoxic drugs is more ambiguous and requires prospective assessment. The available literature is reviewed herein, with a focus on the predictive value of HER2, potential mechanisms of resistance and sensitivity to various drugs, and future research directions involving this important molecule.
Insights
Identifying HER2 (Human Epidermal growth factor Receptor 2) as a biomarker predicts breast cancer treatment response. Research explores HER2-targeted therapies and drug combinations to improve patient survival in early and advanced disease.
Area of Science:
- Oncology
- Molecular Biology
- Translational Research
Background:
- Breast cancer research focuses on identifying predictive markers for targeted therapies.
- HER2/neu (Human Epidermal growth factor Receptor 2) is a key transmembrane tyrosine kinase receptor investigated for its role in breast cancer.
- HER2 overexpression is linked to poorer survival outcomes in breast cancer patients.
Purpose of the Study:
- To review the predictive value of HER2 in breast cancer treatment response.
- To explore mechanisms of sensitivity and resistance to HER2-targeted and cytotoxic therapies.
- To outline future research directions for HER2-based therapeutic strategies.
Main Methods:
- Review of existing literature on HER2 in breast cancer.
- Analysis of retrospective and prospective clinical trial data.
- Examination of molecular mechanisms underlying HER2 function and therapeutic targeting.
Main Results:
- HER2 overexpression is associated with decreased disease-free and overall survival.
- Antibodies targeting HER2 have shown efficacy in advanced breast cancer with HER2 overexpression.
- Combination therapies involving HER2 antibodies and cytotoxic drugs improve survival in metastatic breast cancer.
Conclusions:
- HER2 is a significant predictive marker for response to specific breast cancer therapies, particularly antibody-mediated treatments.
- The role of HER2 in predicting response to hormone therapy and conventional cytotoxic drugs requires further prospective validation.
- Targeting HER2 offers a promising strategy for improving survival in early and advanced breast cancer.